Now, a narrative review published in Frontiers in Human Neuroscience by researchers at Heilongjiang University of Chinese Medicine has taken a fresh, disciplined look at one of the most debated genetic suspects: apolipoprotein E4, the protein product of the APOE ε4 allele. ApoE4 is best known as the strongest common genetic risk factor for sporadic Alzheimer’s disease, but its role in the small vessel disease that damages white matter has remained murky. The review’s central argument is methodological rather than dramatic: much of what scientists believe about ApoE4 and small vessel disease has been inferred from Alzheimer’s disease research, and those inferences risk overstating causal relationships. The authors therefore re-evaluated the evidence using a CSVD-centric hierarchy, sorting claims into direct evidence from defined CSVD populations, suggestive evidence from disease-relevant models, and indirect or speculative evidence drawn mainly from Alzheimer’s studies or cell cultures.

The structural biology of ApoE explains why the isoforms behave differently. ApoE is a 299-amino-acid lipid transport protein with three common variants encoded by the APOE ε2, ε3, and ε4 alleles. ApoE4 carries arginine at position 112, which reorients the side chain of arginine 61 and allows it to interact with glutamate 255 in the protein’s C-terminal domain. This so-called domain interaction produces a more compact conformation than ApoE3, altering lipid binding, lipoprotein assembly, intracellular transport, and lipid delivery. These biophysical differences ripple outward into lysosomal-autophagic function, mitochondrial homeostasis, and inflammatory responses, though the review notes that most of this molecular detail comes from neurodegenerative disease models. In the brain, ApoE is produced primarily by astrocytes under physiological conditions, with microglia and neurons capable of upregulating expression under stress, and ABCA1-dependent lipidation is crucial for forming functional ApoE-containing lipoprotein particles.

When the authors turned to human epidemiological and imaging data, the picture that emerged was one of modest, context-dependent effects rather than a uniform causal signal. In the Rotterdam Scan Study of 971 participants, ε4 carriers showed greater subcortical white matter lesion volumes than ε3/ε3 subjects, and participants with both hypertension and the ε4 allele carried the highest lesion burden, with a statistically significant interaction effect. That finding supports a gene-environment interaction model rather than genotype alone. A longitudinal analysis of 135 cognitively normal adults from the ADNI cohort found that ε4 carriers had greater frontal white matter hyperintensity burden and faster progression, along with more basal ganglia perivascular spaces, but because the cohort included amyloid biomarkers and associations with amyloid-beta were observed, those results cannot be cleanly attributed to non-amyloid small vessel disease.

Pooled evidence underscores the inconsistency. A 2024 meta-analysis of 12 studies and 16,738 adults found no statistically significant overall difference in white matter hyperintensity volume between ε4 carriers and non-carriers, with only a modest association in community-based populations and null results in clinical cohorts. A 2025 NEUROGEN-SVD meta-analysis did find that ε4 carriage was associated with global cognitive impairment in CSVD study populations, with an odds ratio of 1.80, but heterogeneity across studies was high and certainty of evidence was low. More recent studies enrolling CSVD patients specifically have shown greater phenotypic specificity: in 717 CSVD patients, ε4 gene dosage showed a dose-dependent relationship with cognitive decline and white matter hyperintensity severity, while in 728 patients with chronic lacunar infarction, ε4 was independently associated only with periventricular white matter hyperintensity burden, not with microbleeds or enlarged perivascular spaces. The emerging picture is that APOE ε4 acts as a susceptibility modifier whose effects depend on gene dosage, ancestry, age, sex, vascular risk exposure, and co-existing Alzheimer’s pathology.

The review also draws a sharp line between cerebral amyloid angiopathy and sporadic arteriolosclerotic CSVD. Cerebral amyloid angiopathy involves deposition of amyloid-beta in cortical and leptomeningeal vessels and is closely tied to lobar microbleeds and intracerebral hemorrhage. Because APOE ε4 clearly promotes cerebral amyloid deposition, findings from CAA studies cannot be cited as evidence that ApoE4 causes the hypertensive, arteriolosclerotic form of small vessel disease. The authors argue that lobar white matter hyperintensities and CAA should be treated as an amyloid-related small vessel phenotype, and that deep microbleeds, lacunes, and basal ganglia perivascular spaces should be analyzed separately whenever possible.

On the mechanistic front, the strongest CSVD-specific evidence concerns endothelial dysfunction, blood-brain barrier leakage, neurovascular unit instability, and white matter injury. Recent human imaging has reinforced this foundation: dynamic contrast-enhanced MRI in 59 CSVD patients revealed spatially heterogeneous BBB leakage, with a higher proportion of tissue within white matter hyperintensities showing leakage and abnormalities extending into normal-appearing white matter. A longitudinal study of 50 subjects with chronic cerebrovascular disease found that greater baseline BBB disruption predicted more pronounced subsequent white matter hyperintensity progression. But these studies establish BBB dysfunction as part of the CSVD process without proving that ApoE4 is the causative factor. The most compelling ApoE4-specific evidence comes from vascular stress models: in ApoE4-targeted replacement mice subjected to chronic cerebral hypoperfusion, ApoE4 exacerbated reductions in white matter microvascular flow, local hypoxia, white matter injury, and cognitive dysfunction compared with ApoE3. Because the experimental stressor is vascular hypoperfusion rather than amyloid, these findings represent some of the strongest mechanistic links between ApoE4 and a CSVD-like phenotype.

Other proposed mechanisms fare less well under the CSVD-centric lens. The cyclophilin A-MMP-9 pathway, implicated in ApoE4-associated BBB breakdown, remains indirect evidence in the small vessel disease context. The TREM2-ApoE microglial program, insulin receptor trafficking, reelin-related synaptic signaling, endoplasmic reticulum stress, and autophagy all rely primarily on Alzheimer’s research or preclinical systems. Two recently proposed frameworks, the brain-heart-kidney axis hypothesis and the microglial lipid droplet model, offer valuable conceptual scaffolds. The lipid droplet hypothesis, published in 2025, proposes that BBB dysfunction and systemic lipid exposure promote microglial lipid droplet accumulation, contributing to white matter hyperintensity formation, with ApoE4 and ACSL1 linked to accelerated droplet formation. The review emphasizes that this is a testable theory, not an established mechanism, and that the temporal relationship between lipid droplet formation and white matter damage remains unknown.

On the therapeutic front, the review is blunt: no ApoE4-targeted intervention has been proven effective for CSVD-related cognitive impairment. Potential platforms include ApoE4 structural correctors such as GIND25 and PH002, ApoE-mimetic peptides, enhancement of ABCA1-dependent lipidation through LXR/RXR agonists, receptor trafficking modulation, and immunotherapy targeting ApoE4, but all remain exploratory. The authors caution that excessive neutralization of ApoE could compromise its beneficial roles in lipid transport, tissue repair, and immunomodulation, making vascular safety assessment essential. In the meantime, standardized management of modifiable vascular risk factors, particularly hypertension, diabetes, smoking, and dyslipidemia, remains more directly aligned with established CSVD biology.

The review closes with a research agenda that prioritizes genotype-stratified longitudinal CSVD cohorts, standardized imaging protocols, adjustment for Alzheimer’s biomarkers, analysis of vascular risk factor interactions, studies of human white matter tissue, and disease models that integrate chronic hypoperfusion with vascular comorbidities. The bottom line is nuanced but important: ApoE4 is best understood as a modifier of cerebrovascular susceptibility rather than a direct causative gene for sporadic small vessel disease. Only by rigorously separating direct CSVD evidence from mechanistic inferences borrowed from Alzheimer’s disease can researchers determine whether ApoE4 might eventually serve as a reliable biomarker or therapeutic target for vascular cognitive impairment, one of the most common yet least understood threats to the aging brain.

Subject of Research: The role of apolipoprotein E4 in cerebral small vessel disease-related cognitive impairment

Article Title: Emerging roles of apolipoprotein E4 in cerebral small vessel disease-related cognitive impairment: mechanistic insights and therapeutic perspectives

Article References: Li, M., Zhang, Y., Lü, P., Li, J., Zhang, Y., Wang, S., Bai, Y., & Wang, Y. (2026). Emerging roles of apolipoprotein E4 in cerebral small vessel disease-related cognitive impairment: mechanistic insights and therapeutic perspectives. Frontiers in Human Neuroscience, 20, Article 1957032. https://doi.org/10.3389/fnhum.2026.1957032

Image Credits: AI Generated

DOI: 10.3389/fnhum.2026.1957032

Keywords: ApoE4, cerebral small vessel disease, vascular cognitive impairment, white matter hyperintensities, blood-brain barrier, neurovascular unit, microglial lipid droplets, APOE ε4, cerebral amyloid angiopathy, endothelial dysfunction, chronic hypoperfusion, Alzheimer's disease